How life sciences companies can use affiliations data to track non-traditional healthcare services.
Psychedelic-assisted therapies with MDMA and psilocybin are poised to transform the treatment options for a variety of hard-to-treat mental illnesses. However, psychedelics face regulatory and commercial headwinds, which manufacturers will need to navigate for psychedelics to achieve their full potential. Now may be a unique opportunity for investors to contribute to the development of psychedelics […]
An exploration within the growing CDMO space of manufacturing capabilities and efficiencies that support development of complex, innovative proteins / biologics, which continue to be increasingly pertinent and relevant in the market.
ClearView Healthcare Partners, the leading life sciences strategic consultancy supporting Pharma and Biotech globally, is excited to welcome our new Chief People Officer, Kristine Hyde. Over the past 30 years, Kristine has served as Chief People Officer in multiple consulting organizations leading all aspects of the people function, as well as having played various business […]
This August, ClearView Healthcare Partners had the pleasure of welcoming Laurel Sweeney and Andy Molnar for a panel discussion on the challenges and strategic approaches to secure reimbursement for digital health technologies – thank you to both for participating!
• GHO partnering with existing management team to accelerate global growth • ClearView positioned as market leader in an industry experiencing strong tailwinds • Management to pursue international markets and broaden service offering, leveraging GHO’s unparalleled sector expertise
ClearView Healthcare Partners, a strategy consulting firm focused in the life sciences, announces the opening of two new offices in London and Zurich, which will strengthen the company's partnerships with both European-based and global life science organizations.
What are the key features of a propriety diagnostic tool that would enable isolation of a unique market opportunity? What is the business model that should be deployed to incentivize investment in this type of tool? In this paper, we will outline the answers to these questions and provide some examples of exciting technologies which may tap this potential.
Exploration of the value potential of digital therapeutics across biopharma portfolios to help companies gain a competitive edge
We have watched in pain, anger, and frustration at the events unfolding across the nation. George Floyd, Breonna Taylor, Ahmaud Arbery, and countless others are victims of bigotry, hate, and systemic racism that oppresses and devalues black lives that must not be allowed to continue. ClearView stands with our black colleagues, and with all affected […]
With COVID-19, BioPharma companies building out commercial teams are facing a reckoning: How will sales reps sell to physicians? And what does that mean for the size and makeup of my commercial team? Join ClearView Managing Director, Debbi Amanti Belanger, and Dave Melville from the Bowdoin Group on September 23rd to learn more about the […]
San Francisco, CA January 13 – 16, 2020 The ClearView leadership team will be attending this industry-leading healthcare investment symposium.
Current state and future trajectory of digital health including the actionable ways in which digital health can be uniquely leveraged to fill voids in the healthcare system
Hamburg, Germany November 11 – 13, 2019 Several members of the ClearView team including Kim Goh and Sam Ulin will be attending BIO-Europe 2019 in Hamburg. Please reach out if you are onsite attending – we look forward to seeing you!
Sidnee Pinho joins ClearView as the Chief Operating Officer
Several members of leadership team will be joining the discussion with global healthcare leaders at ISPOR Europe
Principal Ryan Tubman and Head of Analytics Mike Roy present a poster at the annual meeting of the American College of Epidemiology
Principal Charles Matthews will be attending to engage in collaboration and networking
Key guiding principles for effective forecasting, common pitfalls, and how to use a forecast to develop better strategy
Presented at the 2019 BIO International Convention in Philadelphia, this talk by Sam Ulin, Managing Director, examines the drivers of value for innovators, with a focus on the technologies and applications that attracted significant funding in 2018
At BIO International Convention in Philadelphia on June 3, 2019, Managing Director Sam Ulin will give lead the Super Session talk, "What’s Next: The Landscape of Innovation in 2019 and Beyond"
David Gilman joins ClearView as a new Partner
As genetic testing becomes more accessible, how are companies incorporating these technologies into their strategy?
RWE has become increasingly important in supporting supplemental or conditional drug approvals. Where is the space headed?
Managing Directors Phil Kenner and Seth Berman will be attending this springtime partnering conference
What are the implications of the DHHS' new plan to overhaul prescription drug rebates for federal beneficiaries?
The ClearView leadership team will be attending this industry-leading healthcare investment symposium
Launching a new therapy is a complex endeavor. We will review the various activities key to a successful drug launch.
How can flexibility in clinical development can be incorporated at various points along an asset’s life cycle
Kim Goh joins the firm's leadership team as a Principal